Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

NCT03750669 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

324

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma Resectable
Neoadjuvant Chemotherapy

Interventions

DRUG: AG regimen
DRUG: mFolfirinox

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University